Developer docs
API playgroundTry for free, no card

Search company profiles

HCS PHARMA

Full company profile

uuid0002vbr

Namestring
HCS PHARMA
Legal namestring
HCS Pharma
Websiteurl
hcs-pharma.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

HCS PHARMA is a privately-held life-sciences company founded in 2014 and headquartered in Loos, France, with a stated headcount of 1-10 employees. The company's core proprietary technology is BIOMIMESYS®, a patented 3D cell culture platform built on the Hydroscaffold™ system, which combines the structural properties of solid scaffolds with the dynamic characteristics of hydrogels. Matrices are composed primarily of Hyaluronic Acid, collagens, and adhesion proteins, with tunable Elastic Modulus, porosity, and density enabling recreation of tissue-specific microenvironments (liver, brain, heart, bone, skin) for drug discovery, disease modeling, tissue engineering, and cell therapy research applications.

Separately, the company operates hcs-pharma.com, a multilingual peptide review and rating platform spanning 9 country editions (UK, Netherlands, France, US, Sweden, Australia, Germany, Denmark, Austria). The site publishes structured five-criterion supplier evaluations, third-party laboratory test results (notably from Janoshik Analytical), and country-specific peptide guides covering products such as Retatrutide, Semaglutide, Tirzepatide, Cagrisema, Cagrilintide, Ipamorelin, NAD+, MOTS-c, Semax, Melanotan 1, BPC-157, TB-500, and LL-37. The platform distributes exclusive affiliate discount codes (HCS-P1-10, RETA20) that route consumer demand primarily to partner supplier LeoLab across multiple geographies.

HCS Pharma's business model combines two distinct revenue mechanics: (1) affiliate referral commissions generated when visitors click through to partner peptide suppliers and complete purchases, and (2) BIOMIMESYS® product sales targeted at biomedical research and drug development laboratories. The company has raised approximately $26M across disclosed funding rounds (notably a 2021 round led by The Global Emerging Markets Group and a 2022 follow-on), with early backing from Eurasante. Pricing for BIOMIMESYS® is not publicly disclosed, and no revenue figures have been made available.

Short descriptiontext

HCS PHARMA is a French life-sciences company that develops BIOMIMESYS®, a patented 3D cell culture technology for drug discovery and disease modeling, while also operating a multilingual 9-country peptide review and affiliate-referral platform routing consumer demand to partner suppliers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLoos, France
HQ citystring
Loos
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
3D cell culture, extracellular matrix scaffolds, drug discovery tools, tissue engineering materials, biomedical research reagents
Industry3 codes
PRIMARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Medicinal and Botanical Manufacturing325411
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Laboratory Analytical Instruments3826
Product category
3D Cell Culture Technology
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Affiliate Referral Commissions
TypeAffiliate Referral
Description

HCS Pharma's primary revenue stream is affiliate referral commissions earned when site visitors click through to partner peptide suppliers (notably LeoLab across multiple country sites) and complete purchases. The site acts as a content discovery and conversion layer, with discount codes (HCS-P1-10 for 10% off; RETA20 for £20 off Retatrutide 10mg) tracked back to HCS Pharma.

hcs-pharma.com
2BIOMIMESYS® 3D Cell Culture Product Sales
TypeHardware Sales
Description

HCS Pharma also develops and supplies BIOMIMESYS®, a patented 3D cell culture product line targeted at biomedical research and drug development customers. Revenue mechanics are not publicly disclosed but the product is positioned for laboratory/research procurement.

hcs-pharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details3 tiers
1HCS-P1-10 promo code: 10% off orders at LeoLab partner suppliers
ModelOtherBilling cadencePay-as-you-go
Notes

Exclusive 10% discount code provided by hcs-pharma.com; can be combined with bulk order discounts at supplier checkout; no minimum order disclosed.

hcs-pharma.com
2RETA20 promo code: £20 off Retatrutide 10mg
ModelOtherBilling cadencePay-as-you-go
Notes

£20 fixed discount on Retatrutide 10mg only; valid until 2025-09-30; limit 1 item per order; 1 use per customer; cannot be combined with other offers; customers must be 18+.

hcs-pharma.com
3Referenced peptide pricing at partner supplier LeoLab UK
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Retatrutide 10mg £170 to 60mg £575; Semaglutide 5mg £100, 10mg £150, 15mg £190; Tirzepatide 10mg £100–£395 (and 20mg £180, 30mg £250); Cagrisema 5mg £180 to 10mg £260; Cagrilintide 5mg £149, 10mg £249, 20mg £459; Ipamorelin 5mg from £35. Bulk discounts applied automatically at checkout.

hcs-pharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BIOMIMESYS
Description

Patented 3D cell culture technology combining properties of solid scaffolds and hydrogels, using Hydroscaffold technology with Hyaluronic Acid-based matrices for biomedical research applications.

hcs-pharma.com
Core offering1 text field

HCS Pharma develops and supplies BIOMIMESYS®, a patented 3D cell culture technology built on its proprietary Hydroscaffold™ platform that combines solid scaffold properties with hydrogel characteristics to recreate human extracellular matrix. Matrices are composed of Hyaluronic Acid, collagens, and adhesion proteins, with tunable physical properties for drug discovery, disease modeling, tissue engineering, and cell therapy applications. The company also operates a multilingual peptide review and rating website (hcs-pharma.com) covering 9 country markets, routing purchase traffic to partner peptide suppliers via affiliate links and exclusive discount codes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Semaglutide 5mg (LeoLab) third-party tested at 99.981% purity by Janoshik Analytical (task 53115, batch G59785, 22 Nov 2024)
+3 more records
Product overview1 text field

HCS PHARMA operates as a peptide information, review, and rating platform (hcs-pharma.com) that independently evaluates third-party peptide suppliers across multiple markets (UK, US, Netherlands, France, Sweden, Australia, Germany, Denmark, Austria). The site's core offering is its proprietary BIOMIMESYS® 3D cell culture product line built on the patented Hydroscaffold™ technology, which combines scaffold and hydrogel properties to recreate human extracellular matrix for drug discovery, disease modeling, tissue engineering, and cell therapy applications. Beyond BIOMIMESYS®, HCS PHARMA publishes detailed review and rating pages for individual peptides including Retatrutide, Semaglutide, Tirzepatide, Cagrisema (a combination peptide of Cagrilintide and Semaglutide), Cagrilintide, Ipamorelin, NAD+, MOTS-c, Semax, Melanotan 1, Survodutide, BPC-157, TB-500, and LL-37, along with ancillary products like Bacteriostatic Water. The platform distributes exclusive discount codes (such as RETA20 and HCS-P1-10) for purchases through partner peptide suppliers such as LeoLab UK, and surfaces independent third-party lab testing results (e.g., Janoshik Analytical) to verify peptide purity. HCS PHARMA also provides localized versions of its review content across nine language/market editions.

Product and service1 record
1BIOMIMESYS® 3D Cell Culture Matrices
Category3D Cell Culture Technology
Description

BIOMIMESYS® is a patented 3D cell culture technology that combines the properties of solid scaffolds and hydrogels to recreate the human extracellular matrix. Built on the proprietary Hydroscaffold™ platform, it uses Hyaluronic Acid, collagens, and adhesion proteins to mimic various tissue microenvironments (liver, brain, heart, bone, skin) with tunable physical properties. Designed for biotech and pharmaceutical researchers conducting drug discovery, disease modeling, tissue engineering, and cell therapy research who need more physiologically relevant in vitro models than traditional 2D cultures.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

LeoLab is HCS Pharma's primary channel partner, featured as the top-rated UK peptide supplier with affiliate referral links from every UK edition peptide page (Retatrutide, Semaglutide, Tirzepatide, Cagrisema, Cagrilintide, Ipamorelin, and others) to leolab.uk. HCS Pharma distributes two exclusive discount codes for LeoLab: HCS-P1-10 (10% off all orders) and RETA20 (£20 off Retatrutide 10mg). Third-party testing verification from Janoshik Analytical is published on HCS Pharma's site for LeoLab products (e.g., Semaglutide 99.981% purity, Tirzepatide 99.776%, Cagrilintide 99.516%).

2LeoLab (EU country variants: leolab-shop.com, leolabshop.com, leolab.se)
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

LeoLab's regional storefronts (leolab-shop.com, leolabshop.com, leolab.se) serve as the destination affiliate links across HCS Pharma's NL, FR, DE, DK, SE, and AT editions. Each country-localized peptide page (Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Semaglutide, Survodutide) routes to the appropriate LeoLab country storefront.

hcs-pharma.com
3LeoLab Rx (leolabrx.com)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

LeoLab Rx (leolabrx.com) is the US-edition affiliate destination for HCS Pharma's en-us site. Each peptide page (Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Survodutide) links to the LeoLab Rx US storefront.

hcs-pharma.com
4LeoLab Australia / South Africa storefronts (leolabpeptides.com, shop.leolab.co.za)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

LeoLab's Australian (leolabpeptides.com) and South African (shop.leolab.co.za) storefronts are the affiliate destinations for HCS Pharma's en-au edition. Peptide pages link to these regional storefronts for Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Survodutide, and TB-500.

hcs-pharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured peptide brands in HCS Pharma's NL edition ranking for trusted Dutch peptide suppliers, highlighted for strict production controls, certification (Bachem, Biosynth, Eurogentec), and distributor reputation (Bio-Connect, LeoLab).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured peptide brands in HCS Pharma's FR edition ranking for trusted French peptide suppliers, highlighted for scientific expertise, traceability (ProteoGenix, Biolab Shop), collagen-based peptide products (Vital Proteins), French natural-quality focus (Nutripure), and scientific orientation (SB-PEPTIDE).

7Core Peptides, Phoenix Pharmaceuticals, GenScript, Aapptec Peptides (US)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured US peptide brands in HCS Pharma's en-us edition ranking, recognized for verifiable purity data, third-party lab testing, consistent service, and reliable delivery across the US market.

hcs-pharma.com
8Nordic Biosite, Kronans Apotek (Sweden)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured Swedish peptide brands in HCS Pharma's sv-se edition ranking, recognized for consistent product quality, clear communication (Nordic Biosite), and customer service / product traceability (Kronans Apotek).

hcs-pharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured Australian peptide brands in HCS Pharma's en-au edition ranking alongside LeoLab, recognized for industry presence, customer reviews, professional reputation, and compliance with local standards.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured German peptide brands in HCS Pharma's de-de edition ranking, recognized for strict quality standards, transparent product information, certified purity, and professional service.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured Danish peptide brands in HCS Pharma's da-dk edition ranking, recognized for stability, transparency, and high European production standards.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Featured Austrian peptide brands in HCS Pharma's de-at edition ranking, alongside LeoLab, BPS Pharma, and Biomol GmbH, recognized for solid reputation as quality peptide sources.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Referenced as an alternative UK supplier of Tirzepatide 10mg vials at £180 each, with multibuy discounts (5% on 3 units, up to 20% on 6 units), mentioned in the HCS Pharma Tirzepatide review as an alternative to LeoLab.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed alongside LeoLab as trusted UK peptide brands recognized for offering peptides that meet high purity standards, transparent testing, reliable shipping, and positive customer experiences within HCS Pharma's UK evaluation.

Strategic tierMinorTypeGTM or Marketing Partner
Description

NICE (the UK health authority) logo is displayed in the footer of hcs-pharma.com across multiple country editions (UK, NL, FR, US, SE, AU, DE, DK, AT, Best Sellers page), suggesting a citation/credibility reference linked to nice.org.uk.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bioprocessing and cell-line development vendor with growing cell-culture and cell-model offerings. Comparable as a broad incumbent serving similar biotech/pharma R&D customers with overlapping technology categories.

2CN Bio Innovations
TypeEmerging player
Description

Developer of organ-on-chip and microphysiological systems for drug discovery and disease modeling. Comparable as a smaller specialist in advanced in vitro models competing for similar 3D/organ-mimetic use cases as BIOMIMESYS®.

3Corning Life Sciences (Matrigel)
TypeBroad incumbent
Description

Corning's Matrigel is the dominant ECM-mimetic basement-membrane matrix used in 3D cell culture, cancer biology, and stem-cell workflows. Directly comparable as a competing 3D/ECM scaffold technology targeting the same biomedical research customers as BIOMIMESYS®.

4Merck KGaA (Sigma-Aldrich / MilliporeSigma)
TypeBroad incumbent
Description

MilliporeSigma sells ECM components, hydrogels, and 3D culture reagents used in drug discovery and tissue engineering — directly overlapping with BIOMIMESYS®'s hydroscaffold/hyaluronic-acid-based ECM applications.

TypeEmerging player
Description

Organ-on-chip platform company targeting preclinical drug-development workflows. Comparable as an emerging player in physiologically relevant in vitro models, competing with BIOMIMESYS® for tissue-specific 3D culture adoption.

TypeBroad incumbent
Description

Major life-sciences tools vendor offering Gibco cell-culture media, matrices, and 3D culture systems. Comparable as a broad incumbent with overlapping 3D cell culture and drug-discovery product portfolio that competes for the same biotech R&D budget.

TypeEmerging player
Description

Organ-on-chip and 3D tissue model company (OrganoPlate) serving pharma toxicology and disease-modeling customers. Comparable as an emerging 3D cell-culture platform peer with similar disease-modeling positioning.

8Examine.com
TypeDirect peer
Description

Independent research-driven supplement and compound review site with affiliate monetization. Comparable as a content/affiliate peer for the peptide-review site business line, though without the BIOMIMESYS® biotech product overlap.

TypeEmerging player
Description

Multi-organ-chip and microphysiological systems company based in Europe. Comparable as a European emerging peer in the 3D/advanced in vitro model category with overlapping drug-discovery applications.

TypeBroad incumbent
Description

Global CDMO and cell-and-gene-therapy solutions provider with extensive cell-culture product lines including primary cells, media, and 3D culture systems. Comparable as a broad incumbent in the cell-culture and drug-discovery tools space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HCS PHARMA

3D Cell Culture Technologyhcs-pharma.com

HCS PHARMA is a French life-sciences company that develops BIOMIMESYS®, a patented 3D cell culture technology for drug discovery and disease modeling, while also operating a multilingual 9-country peptide review and affiliate-referral platform routing consumer demand to partner suppliers.

What HCS PHARMA does

HCS PHARMA is a privately-held life-sciences company founded in 2014 and headquartered in Loos, France, with a stated headcount of 1-10 employees. The company's core proprietary technology is BIOMIMESYS®, a patented 3D cell culture platform built on the Hydroscaffold™ system, which combines the structural properties of solid scaffolds with the dynamic characteristics of hydrogels. Matrices are composed primarily of Hyaluronic Acid, collagens, and adhesion proteins, with tunable Elastic Modulus, porosity, and density enabling recreation of tissue-specific microenvironments (liver, brain, heart, bone, skin) for drug discovery, disease modeling, tissue engineering, and cell therapy research applications.

Separately, the company operates hcs-pharma.com, a multilingual peptide review and rating platform spanning 9 country editions (UK, Netherlands, France, US, Sweden, Australia, Germany, Denmark, Austria). The site publishes structured five-criterion supplier evaluations, third-party laboratory test results (notably from Janoshik Analytical), and country-specific peptide guides covering products such as Retatrutide, Semaglutide, Tirzepatide, Cagrisema, Cagrilintide, Ipamorelin, NAD+, MOTS-c, Semax, Melanotan 1, BPC-157, TB-500, and LL-37. The platform distributes exclusive affiliate discount codes (HCS-P1-10, RETA20) that route consumer demand primarily to partner supplier LeoLab across multiple geographies.

HCS Pharma's business model combines two distinct revenue mechanics: (1) affiliate referral commissions generated when visitors click through to partner peptide suppliers and complete purchases, and (2) BIOMIMESYS® product sales targeted at biomedical research and drug development laboratories. The company has raised approximately $26M across disclosed funding rounds (notably a 2021 round led by The Global Emerging Markets Group and a 2022 follow-on), with early backing from Eurasante. Pricing for BIOMIMESYS® is not publicly disclosed, and no revenue figures have been made available.

HCS PHARMA firmographics

Firmographics
Name
HCS PHARMA
Legal name
HCS Pharma
Website
https://hcs-pharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
HCS PHARMA is a French life-sciences company that develops BIOMIMESYS®, a patented 3D cell culture technology for drug discovery and disease modeling, while also operating a multilingual 9-country peptide review and affiliate-referral platform routing consumer demand to partner suppliers.
Ownership category
akta.pro rank

HCS PHARMA industry classification

Industry
Product category
3D Cell Culture Technology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • 3D cell culture
  • Extracellular matrix scaffolds
  • Drug discovery tools
  • Tissue engineering materials
  • Biomedical research reagents

Where HCS PHARMA is headquartered

Location

Headquarters

HQ city
Loos
HQ country
France
HQ region
Europe

Markets served

HCS PHARMA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Affiliate Referral Commissions: HCS Pharma's primary revenue stream is affiliate referral commissions earned when site visitors click through to partner peptide suppliers (notably LeoLab across multiple country sites) and complete purchases. The site acts as a content discovery and conversion layer, with discount codes (HCS-P1-10 for 10% off; RETA20 for £20 off Retatrutide 10mg) tracked back to HCS Pharma.
  2. BIOMIMESYS® 3D Cell Culture Product Sales: HCS Pharma also develops and supplies BIOMIMESYS®, a patented 3D cell culture product line targeted at biomedical research and drug development customers. Revenue mechanics are not publicly disclosed but the product is positioned for laboratory/research procurement.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goHCS-P1-10 promo code: 10% off orders at LeoLab partner suppliers
OtherPay-as-you-goRETA20 promo code: £20 off Retatrutide 10mg
Unit PricingPay-as-you-goReferenced peptide pricing at partner supplier LeoLab UK

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

HCS PHARMA product offering

Product offering

Core offering

HCS Pharma develops and supplies BIOMIMESYS®, a patented 3D cell culture technology built on its proprietary Hydroscaffold™ platform that combines solid scaffold properties with hydrogel characteristics to recreate human extracellular matrix. Matrices are composed of Hyaluronic Acid, collagens, and adhesion proteins, with tunable physical properties for drug discovery, disease modeling, tissue engineering, and cell therapy applications. The company also operates a multilingual peptide review and rating website (hcs-pharma.com) covering 9 country markets, routing purchase traffic to partner peptide suppliers via affiliate links and exclusive discount codes.

Product overview

HCS PHARMA operates as a peptide information, review, and rating platform (hcs-pharma.com) that independently evaluates third-party peptide suppliers across multiple markets (UK, US, Netherlands, France, Sweden, Australia, Germany, Denmark, Austria). The site's core offering is its proprietary BIOMIMESYS® 3D cell culture product line built on the patented Hydroscaffold™ technology, which combines scaffold and hydrogel properties to recreate human extracellular matrix for drug discovery, disease modeling, tissue engineering, and cell therapy applications. Beyond BIOMIMESYS®, HCS PHARMA publishes detailed review and rating pages for individual peptides including Retatrutide, Semaglutide, Tirzepatide, Cagrisema (a combination peptide of Cagrilintide and Semaglutide), Cagrilintide, Ipamorelin, NAD+, MOTS-c, Semax, Melanotan 1, Survodutide, BPC-157, TB-500, and LL-37, along with ancillary products like Bacteriostatic Water. The platform distributes exclusive discount codes (such as RETA20 and HCS-P1-10) for purchases through partner peptide suppliers such as LeoLab UK, and surfaces independent third-party lab testing results (e.g., Janoshik Analytical) to verify peptide purity. HCS PHARMA also provides localized versions of its review content across nine language/market editions.

Differentiator

Problem solved

Functional benefit

Brands

  • BIOMIMESYS: Patented 3D cell culture technology combining properties of solid scaffolds and hydrogels, using Hydroscaffold technology with Hyaluronic Acid-based matrices for biomedical research applications.

Products and services

  • BIOMIMESYS® 3D Cell Culture Matrices BIOMIMESYS® is a patented 3D cell culture technology that combines the properties of solid scaffolds and hydrogels to recreate the human extracellular matrix. Built on the proprietary Hydroscaffold™ platform, it uses Hyaluronic Acid, collagens, and adhesion proteins to mimic various tissue microenvironments (liver, brain, heart, bone, skin) with tunable physical properties. Designed for biotech and pharmaceutical researchers conducting drug discovery, disease modeling, tissue engineering, and cell therapy research who need more physiologically relevant in vitro models than traditional 2D cultures.

Quantifiable outcome

  • Semaglutide 5mg (LeoLab) third-party tested at 99.981% purity by Janoshik Analytical (task 53115, batch G59785, 22 Nov 2024)
  • +3 more outcomes

Companies that use HCS PHARMA

Customer profile

Segments5 records

Ideal customer profiles2 records

HCS PHARMA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

HCS PHARMA partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered flagship, core and minor.

  • LeoLabflagshipChannel Partner/ Reseller/ DistributorLeoLab is HCS Pharma's primary channel partner, featured as the top-rated UK peptide supplier with affiliate referral links from every UK edition peptide page (Retatrutide, Semaglutide, Tirzepatide, Cagrisema, Cagrilintide, Ipamorelin, and others) to leolab.uk. HCS Pharma distributes two exclusive discount codes for LeoLab: HCS-P1-10 (10% off all orders) and RETA20 (£20 off Retatrutide 10mg). Third-party testing verification from Janoshik Analytical is published on HCS Pharma's site for LeoLab products (e.g., Semaglutide 99.981% purity, Tirzepatide 99.776%, Cagrilintide 99.516%).
  • LeoLab (EU country variants: leolab-shop.com, leolabshop.com, leolab.se)flagshipChannel Partner/ Reseller/ DistributorLeoLab's regional storefronts (leolab-shop.com, leolabshop.com, leolab.se) serve as the destination affiliate links across HCS Pharma's NL, FR, DE, DK, SE, and AT editions. Each country-localized peptide page (Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Semaglutide, Survodutide) routes to the appropriate LeoLab country storefront.
  • LeoLab Rx (leolabrx.com)coreChannel Partner/ Reseller/ DistributorLeoLab Rx (leolabrx.com) is the US-edition affiliate destination for HCS Pharma's en-us site. Each peptide page (Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Survodutide) links to the LeoLab Rx US storefront.
  • LeoLab Australia / South Africa storefronts (leolabpeptides.com, shop.leolab.co.za)coreChannel Partner/ Reseller/ DistributorLeoLab's Australian (leolabpeptides.com) and South African (shop.leolab.co.za) storefronts are the affiliate destinations for HCS Pharma's en-au edition. Peptide pages link to these regional storefronts for Retatrutide, Tirzepatide, Cagrisema, Cagrilintide, Survodutide, and TB-500.
  • Bachem, Biosynth, Eurogentec, Bio-Connect (Netherlands)minorChannel Partner/ Reseller/ DistributorFeatured peptide brands in HCS Pharma's NL edition ranking for trusted Dutch peptide suppliers, highlighted for strict production controls, certification (Bachem, Biosynth, Eurogentec), and distributor reputation (Bio-Connect, LeoLab).
  • ProteoGenix, Biolab Shop, Vital Proteins, Nutripure, SB-PEPTIDE (France)minorChannel Partner/ Reseller/ DistributorFeatured peptide brands in HCS Pharma's FR edition ranking for trusted French peptide suppliers, highlighted for scientific expertise, traceability (ProteoGenix, Biolab Shop), collagen-based peptide products (Vital Proteins), French natural-quality focus (Nutripure), and scientific orientation (SB-PEPTIDE).
  • Core Peptides, Phoenix Pharmaceuticals, GenScript, Aapptec Peptides (US)minorChannel Partner/ Reseller/ DistributorFeatured US peptide brands in HCS Pharma's en-us edition ranking, recognized for verifiable purity data, third-party lab testing, consistent service, and reliable delivery across the US market.
  • Nordic Biosite, Kronans Apotek (Sweden)minorChannel Partner/ Reseller/ DistributorFeatured Swedish peptide brands in HCS Pharma's sv-se edition ranking, recognized for consistent product quality, clear communication (Nordic Biosite), and customer service / product traceability (Kronans Apotek).
  • Auspep, EHPlabs, PHYX Peptides (Australia)minorChannel Partner/ Reseller/ DistributorFeatured Australian peptide brands in HCS Pharma's en-au edition ranking alongside LeoLab, recognized for industry presence, customer reviews, professional reputation, and compliance with local standards.
  • Biolab Shop, Shop Aphoteke, BPS Pharma, Biomol GmbH (Germany)minorChannel Partner/ Reseller/ DistributorFeatured German peptide brands in HCS Pharma's de-de edition ranking, recognized for strict quality standards, transparent product information, certified purity, and professional service.
  • Orifarm, 2care4 ApS, Apotek Dansk, Sikkert Vægttab ApS (Denmark)minorChannel Partner/ Reseller/ DistributorFeatured Danish peptide brands in HCS Pharma's da-dk edition ranking, recognized for stability, transparency, and high European production standards.
  • Biolabshop.de, Shop-apotheke.at (Austria)minorChannel Partner/ Reseller/ DistributorFeatured Austrian peptide brands in HCS Pharma's de-at edition ranking, alongside LeoLab, BPS Pharma, and Biomol GmbH, recognized for solid reputation as quality peptide sources.
  • Peptagenix PeptidesminorChannel Partner/ Reseller/ DistributorReferenced as an alternative UK supplier of Tirzepatide 10mg vials at £180 each, with multibuy discounts (5% on 3 units, up to 20% on 6 units), mentioned in the HCS Pharma Tirzepatide review as an alternative to LeoLab.
  • UK-Peptides Direct, Pure Peptides UK, Dr Peptides, XL Peptides (UK)minorChannel Partner/ Reseller/ DistributorListed alongside LeoLab as trusted UK peptide brands recognized for offering peptides that meet high purity standards, transparent testing, reliable shipping, and positive customer experiences within HCS Pharma's UK evaluation.
  • National Institute for Health and Care Excellence (NICE)minorGTM or Marketing PartnerNICE (the UK health authority) logo is displayed in the footer of hcs-pharma.com across multiple country editions (UK, NL, FR, US, SE, AU, DE, DK, AT, Best Sellers page), suggesting a citation/credibility reference linked to nice.org.uk.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

HCS PHARMA competitors and assessment

Company assessment

Broad incumbents

  • Sartorius: Bioprocessing and cell-line development vendor with growing cell-culture and cell-model offerings. Comparable as a broad incumbent serving similar biotech/pharma R&D customers with overlapping technology categories.
  • Corning Life Sciences (Matrigel): Corning's Matrigel is the dominant ECM-mimetic basement-membrane matrix used in 3D cell culture, cancer biology, and stem-cell workflows. Directly comparable as a competing 3D/ECM scaffold technology targeting the same biomedical research customers as BIOMIMESYS®.
  • Merck KGaA (Sigma-Aldrich / MilliporeSigma): MilliporeSigma sells ECM components, hydrogels, and 3D culture reagents used in drug discovery and tissue engineering — directly overlapping with BIOMIMESYS®'s hydroscaffold/hyaluronic-acid-based ECM applications.
  • Thermo Fisher Scientific: Major life-sciences tools vendor offering Gibco cell-culture media, matrices, and 3D culture systems. Comparable as a broad incumbent with overlapping 3D cell culture and drug-discovery product portfolio that competes for the same biotech R&D budget.
  • Lonza Group: Global CDMO and cell-and-gene-therapy solutions provider with extensive cell-culture product lines including primary cells, media, and 3D culture systems. Comparable as a broad incumbent in the cell-culture and drug-discovery tools space.

Emerging players

  • CN Bio Innovations: Developer of organ-on-chip and microphysiological systems for drug discovery and disease modeling. Comparable as a smaller specialist in advanced in vitro models competing for similar 3D/organ-mimetic use cases as BIOMIMESYS®.
  • Emulate Inc. Organ-on-chip platform company targeting preclinical drug-development workflows. Comparable as an emerging player in physiologically relevant in vitro models, competing with BIOMIMESYS® for tissue-specific 3D culture adoption.
  • Mimetas: Organ-on-chip and 3D tissue model company (OrganoPlate) serving pharma toxicology and disease-modeling customers. Comparable as an emerging 3D cell-culture platform peer with similar disease-modeling positioning.
  • TissUse: Multi-organ-chip and microphysiological systems company based in Europe. Comparable as a European emerging peer in the 3D/advanced in vitro model category with overlapping drug-discovery applications.

Direct peers

  • Examine.com: Independent research-driven supplement and compound review site with affiliate monetization. Comparable as a content/affiliate peer for the peptide-review site business line, though without the BIOMIMESYS® biotech product overlap.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

HCS PHARMA social profiles

Digital presence

HCS PHARMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HCS PHARMA leadership team

Management profile

Number of profiles

Profiles1 record

HCS PHARMA funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HCS PHARMA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HCS PHARMA

What does HCS PHARMA do?

HCS Pharma develops and supplies BIOMIMESYS®, a patented 3D cell culture technology built on its proprietary Hydroscaffold™ platform that combines solid scaffold properties with hydrogel characteristics to recreate human extracellular matrix. Matrices are composed of Hyaluronic Acid, collagens, and adhesion proteins, with tunable physical properties for drug discovery, disease modeling, tissue engineering, and cell therapy applications. The company also operates a multilingual peptide review and rating website (hcs-pharma.com) covering 9 country markets, routing purchase traffic to partner peptide suppliers via affiliate links and exclusive discount codes.

Is HCS PHARMA a public or private company?

HCS PHARMA is a private company. It is classified as venture growth investor backed and is currently operating.

When was HCS PHARMA founded?

HCS PHARMA was founded in 2014. It employs 1 to 10 people.

Where is HCS PHARMA based?

HCS PHARMA is headquartered in Loos, France, in the Europe region.

How does HCS PHARMA make money?

Two revenue lines are on record. Affiliate Referral Commissions are the primary driver. The others are BIOMIMESYS® 3D Cell Culture Product Sales.

Who are HCS PHARMA's main competitors?

Broad incumbents on record are Sartorius, Corning Life Sciences (Matrigel), Merck KGaA (Sigma-Aldrich / MilliporeSigma), Thermo Fisher Scientific and Lonza Group. Emerging players are CN Bio Innovations, Emulate Inc., Mimetas and TissUse. Examine.com is listed as a direct peer.

Does HCS PHARMA have an API?

No public API is recorded for HCS PHARMA.

What industry is HCS PHARMA in?

HCS PHARMA's product category is 3D Cell Culture Technology. Its primary akta.pro industry code is HLAGANAD, Cellomics & High-Content Screening (HCS) Services, with a secondary code of HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MaddynessEntre BioTech et Industrie 4.0, 7 startups à suivre à Lille en 2022Seven Lille startups are profiled for 2022, covering BioTech, MedTech, FinTech, EdTech, Communication, and Robotics. Exotec's Skypod robot multiplies warehouse productivity by five, while HCS Pharma uses stem cells to create miniature organs for drug testing.CrowdFund InsiderHCS Pharma Pursues Security Token Offering on EDSX, a Digital Securities ExchangeFrench biotech firm HCS Pharma is conducting a pre-IPO security token offering on the European Digital Assets Exchange (EDSX), raising over €2 million of its €7 million goal. The tokens, priced at €1.00 each, represent SAFE agreements that provide investors with a 20% discount on shares when HCS Pharma lists on the Frankfurt Stock Exchange in 2022. EDSX facilitates this process by allowing institutional and retail investors to purchase digital securities without needing blockchain wallet management.PressatFrankfurt Stock Exchange: Pre-IPO of HCS Pharma through a Security Token Offering on the EDSX platformFrench biotech company HCS Pharma is launching a pre-IPO via security tokens on the European Digital Assets Exchange (EDSX) platform, aiming for a €200 million valuation upon its planned 2022 listing on the Frankfurt Stock Exchange. The offering allows investors to purchase tokens representing SAFE agreements at a discount to the future share price, utilizing HCS Pharma's proprietary BIOMIMESYS® cell culture technology. This initiative positions HCS Pharma as the first non-crypto firm to offer pre-IPO equity tokens through this digital asset mechanism.Wayback MachineProjectsHCS PHARMA SAS is offering up to €7,000,000 in unsecured Future Equity Tokens (FETs) convertible into company stock, with a target valuation cap of €200 million. The company aims to go public through a reverse takeover with a listed German entity and has signed an agreement to list on the European Digital Exchange Platform.openPR.comHCS Pharma secures 20 Million EUR capital commitment from the GEM group for the development of BIOMIMESYS® productsHCS Pharma has secured a EUR 20 million capital commitment from the investment group GEM Global Yield LLC SCS to support the development and global commercialization of its BIOMIMESYS® products. The funding is structured as a share subscription facility tied to HCS Pharma's upcoming public listing on a European National Stock Exchange, with proceeds aimed at accelerating drug discovery technology adoption.